兰嘉生物「第二家园基金」重磅发布：锚定中澳产业园

Core Insights - Lanjia Bio has launched the Second Home Fund to enhance Sino-Australian collaboration in the biopharmaceutical sector, focusing on innovation and industry symbiosis [1][4] Group 1: Fund Overview - The Second Home Fund targets cutting-edge areas such as innovative drug development, high-end biological raw materials, AI-driven drug formulation, and cell therapy [3] - The fund aims to create a comprehensive investment ecosystem that connects research, transformation, production, and commercialization [3] Group 2: Industry Collaboration - The Sino-Australian Biopharmaceutical Industry Technology Park serves as a model for international collaboration, housing over 30 leading companies and nurturing several unicorns valued over 1 billion [3] - The park offers shared laboratories, GMP workshops, and innovation centers, facilitating rapid technology transfer and linking Australian advancements with Chinese market opportunities [3] Group 3: Mission and Vision - The fund's mission is to empower innovation and create value by integrating technology platforms, talent resources, and policy support for invested companies [4] - It focuses on breaking global supply chain barriers and supporting projects that fill industry gaps and overcome critical technological challenges [4][5]